Edesa Biotech (Edesa Biotech) FCF Yield % : -42.92 (As of May. 14, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Edesa Biotech FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Edesa Biotech's Trailing 12-Month Free Cash Flow is $-6.25 Mil, and Market Cap is $14.57 Mil. Therefore, Edesa Biotech's FCF Yield % for today is -42.92%.

The historical rank and industry rank for Edesa Biotech's FCF Yield % or its related term are showing as below:

EDSA' s FCF Yield % Range Over the Past 10 Years
Min: -293.32 Med: -23.08 Max: -2.49
Current: -42.92

During the past 13 years, the highest FCF Yield % of Edesa Biotech was -2.49%. The lowest was -293.32%. And the median was -23.08%.

EDSA's FCF Yield % is ranked worse than
72.97% of 1554 companies
in the Biotechnology industry
Industry Median: -14.38 vs EDSA: -42.92

Edesa Biotech's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Edesa Biotech FCF Yield % Historical Data

The historical data trend for Edesa Biotech's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edesa Biotech FCF Yield % Chart

Edesa Biotech Annual Data

Trend

Aug14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

FCF Yield %

Get a 7-Day Free Trial

-10.38

-6.47

-13.93

-80.03

-48.77

Edesa Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial															-17.14	-34.37	-42.67	-43.16	-38.91

Competitive Comparison of Edesa Biotech's FCF Yield %

For the Biotechnology subindustry, Edesa Biotech's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edesa Biotech's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edesa Biotech's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Edesa Biotech's FCF Yield % falls into.

Edesa Biotech FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Edesa Biotech's FCF Yield % for the fiscal year that ended in Sep. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-6.636	/	13.60587928
	=	-48.77%

Edesa Biotech's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-1.407	*	4	/	14.4627704
	=	-38.91%

Edesa Biotech FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Edesa Biotech FCF Yield % Related Terms

Thank you for viewing the detailed overview of Edesa Biotech's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Edesa Biotech (Edesa Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (NAS:EDSA) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Spy Court, Markham, ON, CAN, L3R 5H6

Website

https://www.edesabiotech.com

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Executives

Stephen Lemieux	officer: Chief Financial Officer	100 SPY COURT, C/O EDESA BIOTECH, INC., MARKHAM A6 L3R 5H6
Joan Chypyha	director	100 SPY COURT, MARKHAM A6 L3R 5H6
Patrick Marshall	director	100 SPY COURT, MARKHAM A6 L3R 5H6
Van Der Velden Peter	director, 10 percent owner	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Michael J Brooks	officer: President	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Pardeep Nijhawan	director, 10 percent owner, officer: Chief Executive Officer	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Jennifer M Chao	director	7 PURITAN WOODS ROAD, RYE NY 10580
Frank R. Oakes	director, officer: President, CEO, & Director	C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041
Sean Arthur Macdonald	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lorin K Johnson	director	3600 W BAYSHORE ROAD SUITE 205, PALO ALTO CA 94303
Pardeep Nijhawan Medicine Professional Corp	10 percent owner	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Paul William Pay	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Carlo Sistilli	director	C/O EDESA BIOTECH INC., 100 SPY COURT, MARKHAM A6 L3R 5H6
Lumira Capital Investment Management Inc.	10 percent owner	141 ADELAIDE STREET WEST, SUITE 770, TORONTO A6 M5H 3L5
Daniel E. Morse	director	C/O STELLAR BIOTECHNOLOGIES, INC., 332 EAST SCOTT STREET, PORT HUENEME CA 93041